myeloid leukemia in acute microRNA-181a up-regulates expression of the antileukemic -p30 protein α Lenalidomide-mediated enhanced translation of C/EBP

Prepublished online October 25, 2012; D. Bloomfield, Ramiro Garzon and Guido Marcucci Zhao, Todd A. Fehniger, Ravi Vij, John C. Byrd, William Blum, L. James Lee, Michael A. Caligiuri, Clara Mrózek, Alison Walker, Anna M. Eiring, Susan P. Whitman, Heiko Becker, Danilo Perrotti, Lai-Chu Wu, Xi Santhanam, Anjali Mishra, Yue-Zhong Wu, Houda Alachkar, Kati Maharry, Deedra Nicolet, Krzysztof Christopher J. Hickey, Sebastian Schwind, Hanna S. Radomska, Adrienne M. Dorrance, Ramasamy myeloid leukemia in acute microRNA-181a upregulates expression of the anti-leukemic -p30 protein α Lenalidomide-mediated enhanced translation of C/EBP

[1]  R. Vij,et al.  A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. , 2012, Blood.

[2]  M. Caligiuri,et al.  Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. , 2012, Blood.

[3]  R. Giffard,et al.  miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. , 2012, Mitochondrion.

[4]  M. Boccadoro,et al.  Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. , 2011, Blood.

[5]  L. J. Lee,et al.  Nanochannel electroporation delivers precise amounts of biomolecules into living cells. , 2011, Nature nanotechnology.

[6]  G. Marcucci,et al.  Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells , 2011, The AAPS Journal.

[7]  Erdogan Taskesen,et al.  Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. , 2011, Blood.

[8]  N. Park,et al.  miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. , 2011, Biochemical and biophysical research communications.

[9]  M. Caligiuri,et al.  Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Grever,et al.  Dose escalation of lenalidomide in relapsed or refractory acute leukemias. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Bohlander,et al.  Elevated PIN1 expression by C/EBPα-p30 blocks C/EBPα-induced granulocytic differentiation through c-Jun in AML , 2010, Leukemia.

[12]  M. Caligiuri,et al.  Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. , 2010, Cancer cell.

[13]  M. Caligiuri,et al.  miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts , 2010, Cell.

[14]  E. Hoster,et al.  Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Ryan M. O’Connell,et al.  Physiological and pathological roles for microRNAs in the immune system , 2010, Nature Reviews Immunology.

[16]  R. Månsson,et al.  Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. , 2009, Cancer cell.

[17]  C. Croce,et al.  Karyotype-specific microRNA signature in chronic lymphocytic leukemia. , 2009, Blood.

[18]  T. Pabst,et al.  Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia , 2009, Clinical Cancer Research.

[19]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[20]  Lucy Skrabanek,et al.  Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. , 2009, Blood.

[21]  Christian Langer,et al.  Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Junxia Zhang,et al.  hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells , 2008, Brain Research.

[23]  M. Caligiuri,et al.  MicroRNA expression in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[24]  Torsten Haferlach,et al.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin , 2008, Proceedings of the National Academy of Sciences.

[25]  N. Galili,et al.  An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome , 2008, PLoS medicine.

[26]  D. Tenen,et al.  Target proteins of C/EBPαp30 in AML: C/EBPαp30 enhances sumoylation of C/EBPαp42 via up-regulation of Ubc9 , 2007 .

[27]  S. Bohlander,et al.  Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations , 2006, The Journal of experimental medicine.

[28]  D. Gilliland,et al.  Drug therapy for acute myeloid leukemia. , 2005, Blood.

[29]  N. Timchenko,et al.  Dephosphorylated C/EBPα Accelerates Cell Proliferation through Sequestering Retinoblastoma Protein , 2005, Molecular and Cellular Biology.

[30]  C. Nerlov.  C/EBPα mutations in acute myeloid leukaemias , 2004, Nature Reviews Cancer.

[31]  D. Tenen,et al.  Phosphorylation of C/EBPα Inhibits Granulopoiesis , 2004, Molecular and Cellular Biology.

[32]  B. Calabretta,et al.  Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation. , 2003, Blood.

[33]  Achim Leutz,et al.  Translational control of gene expression and disease. , 2002, Trends in molecular medicine.

[34]  Carl W. Miller,et al.  Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. , 2002, Blood.

[35]  Triona Goode,et al.  C/EBPα Arrests Cell Proliferation through Direct Inhibition of Cdk2 and Cdk4 , 2001 .

[36]  E. Estey.  Therapeutic options for acute myelogenous leukemia , 2001, Cancer.

[37]  C. Bloomfield,et al.  Clinical importance of cytogenetics in acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.

[38]  Pu Zhang,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.

[39]  A. Leutz,et al.  Translational control of C/EBPalpha and C/EBPbeta isoform expression. , 2000, Genes & development.

[40]  D. T. Kurtz,et al.  C/EBPα Inhibits Cell Growth via Direct Repression of E2F-DP-Mediated Transcription , 2000, Molecular and Cellular Biology.

[41]  I. Weissman,et al.  A clonogenic common myeloid progenitor that gives rise to all myeloid lineages , 2000, Nature.

[42]  D. Tenen,et al.  CCAAT/Enhancer Binding Protein α Is a Regulatory Switch Sufficient for Induction of Granulocytic Development from Bipotential Myeloid Progenitors , 1998, Molecular and Cellular Biology.

[43]  J. Schalkwijk,et al.  Transcription Factor C/EBPα: Novel Sites of Expression and Cloning of the Human Gene , 1997, Biological chemistry.

[44]  E. Ziff,et al.  Three levels of functional interaction determine the activity of CCAAT/enhancer binding protein-alpha on the serum albumin promoter. , 1994, Genes & development.

[45]  Zhongwei Cao,et al.  miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis , 2011, Journal of Cancer Research and Clinical Oncology.

[46]  D. Tenen,et al.  Target proteins of C/EBPalphap30 in AML: C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9. , 2007, Blood.

[47]  D. Tenen,et al.  Phosphorylation of C/EBPalpha inhibits granulopoiesis. , 2004, Molecular and cellular biology.

[48]  C. Nerlov.  C/EBPalpha mutations in acute myeloid leukaemias. , 2004, Nature reviews. Cancer.

[49]  Bob Löwenberg,et al.  Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. , 2003, The hematology journal : the official journal of the European Haematology Association.

[50]  R. Koenen,et al.  Articles on similar topics can be found in the following Blood collections Cell Adhesion and Motility (790 articles) , 2004 .

[51]  M. Caligiuri,et al.  BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. , 2002, Nature genetics.

[52]  M. Caligiuri,et al.  BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2 , 2002, Nature Genetics.

[53]  G. Behre,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. , 2001, Nature genetics.

[54]  A. Welm,et al.  C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. , 2001, Molecular cell.

[55]  P. Johnson,et al.  C/EBP proteins contain nuclear localization signals imbedded in their basic regions. , 1997, Gene expression.

[56]  Bas J. Wouters,et al.  Brief Report Results and Discussion , 2022 .